Alex­ion clinch­es aHUS ap­proval for Ul­tomiris as the clock ticks on Soliris con­ver­sion

Alex­ion has racked up a sec­ond ap­proval for Ul­tomiris, the suc­ces­sor ther­a­py to Soliris, as its main­stay block­buster ther­a­py faces a patent re­view process that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER